newsfilter
← Latest News
Earnings Call Transcripts·

UBS Global Biopharma Conference - SEPTERNA INC

Good afternoon, everybody. Welcome to the next session at the UBS Global Biopharma Conference. I'm Alice Nettleton, one of the SMID biotech analysts at UBS. Happy to introduce the team from SEPTURNA, Jeff Feiner, CEO and co-founder, and Liz Butt, president and COO. Great to see you, Jeff and Liz. Thank you so much for joining us. To start off, I'll hand it over to Jeff to go through some slides for a presentation for maybe 15 minutes, and then we'll have a Q&A after that. Okay. Thanks, Alice, and thanks to the UBS team for inviting us. So for those of you who aren't familiar with Cipterna, we're a company focused entirely on GPCRs or G-protein coupled receptors. At the founding of the company, we figured out a new way to do drug discovery for GPCRS. I don't have time today to tell you much about the platform, but I will make some forward-looking statements, so take that into consideration. But that platform has quickly evolved into a very interesting portfolio of products. And we'll spend time on a couple of these today. So SEP479 is our oral small molecule drug for hyperparathyroidism. It's focused on the parathyroid hormone receptor called PTH1R. It's currently in an ongoing phase one trial. We anticipate that that phase one trail will read out in the first quarter of 2027. So we're excited about that data set, and we can spend some of that time today talking about what we hope to see in that data set. Our second program, which is fairly newly announced, is SCP-204. It's going after a target called TSHR for Graves' disease and thyroid eye disease. We just presented, just about a week and a half ago, data at the American Thyroid Association Conference, preclinical data. This is a compound that's moving along quite nicely on the way to starting in the clinic. It should be in the clinic in Q1 of 2027 as well, so it'd be great to introduce you to that as well. A couple other programs that we may only touch on more briefly today. One focus is on a mass cell target called MRG-Perox-2, where we have a compound, SCP-631, that completed a phase one trial in March, and we announced that data. We're excited about that compound. We think we've got a potential best-in-class profile for that compound. It is currently in between phase one and phase two as we are developing a clinical strategy around which indications to go after next. And then the newest addition to our pipeline, the fourth program there, is a second PTH receptor small molecule agonist program. This is for osteoporosis. And one thing that distinguishes the osteoporesis program from the hyperparathyroidism program is that for osteo process, you need to have a short-acting compound. There is something about bone biology and the interaction with the PTH receptor. We know from peptides that short-acting peptides are anabolic for bone. They cause bone formation. Whereas for hypoparathyroidism, we actually want full-day calcium control. So we want a long-acting confound there. Beyond those, we actually have a few earlier stage programs as well we won't talk about those but we also have a quite substantial partnership with novo that we put in place about a little over a year ago now middle of 2025 that collaboration is working on five targets four concurrent programs it's going quite well just last week we we announced in our quarterly earnings that novo had selected the first development candidate from the collaboration and plans to move that forward. Okay, so what I'd like to do with time today is really spend it on two programs, the hyperparathyroidism program and the GRAVES program. So SCP-479 came out of our platform, which we call the Native Complex Platform, and we developed an oral small molecule that's actually quite potent. What we're looking at here is the PTH receptor in magenta, and you can see in green the PTH peptide. PTH peptide basically binds in the transmembrane domain and goes all the way up on the extracellular domain. This is a receptor that many companies have tried to find small molecules for for literally decades and struck out and we found not one binding pocket but two distinct binding pockets for oral small molecules that allow those compounds to completely mimic what the peptides do in every preclinical model system that we've looked at, the small molecule for the PTH receptor, including SCP-479, do exactly what the Pth peptides do. We optimized that with our platform and led to this candidate. And so, as I said, 479 is a potent oral small molecule. As I'll show you, it has some great activity in preclINICAL models. just for the sake of time we'll only focus on one of them today one of the preclinical models but it showed great activity in a rat surgical model of hyperparathyroidism what I'll share today is some monkey PKPD data that isn't a healthy monkey and it's a good predictor of what we hope to see in our healthy patient trial and going that's ongoing it's got great pharmaceutical properties we projected that it would have a half-life between 40 and 80 hours and we ended up at the long end of that we've got a compound that now has a half-life of three to four days which we think is actually quite important because it will allow us to actually achieve ideally very stable calcium control throughout the day well well tolerated in GLP tox studies and as I said it's in phase one trial right now so with regard to that monkey data this is a seven day study in a health healthy monkeys and one thing that's important to realize is that healthy monkeys, as well as healthy humans in our clinical trial, generally have intact parathyroid glands, which is quite different than hyperparathyroidism patients who have frequently lost their parathyroid glands. In a healthy animal and a healthy human, the result of having those glands is that there's an endocrine feedback loop that tries to keep calcium stable. And with that endocrin feedback loop, what we expect to see when we dose our drug is endogenous PTH levels going down. And this is exactly what you're seeing here in the left graph. So this is endogeneous PTH level. And you can see it's percentage change. We're lowering that by about 80% or so. Here, once that is down and hits that threshold, you can kind of see it bottoms out there. We've got four different doses. As we dose up higher, we get increasing levels of calcium beyond that. So the question is, what's the relevant amount of calcium increase that we hope to see? Well, the advantage that we have is that there have been peptides developed before us. And so Urovipath from Ascendis, which is the currently approved drug for injectable peptide for hyperparathyroidism, if we look at their starting dose and then retrospectively look at what it did in its phase one healthy volunteer studies, it increased calcium about 0.5 milligrams per deciliter, which was appropriate for a starting dose, and then up to about one mg per decilitre at higher doses. So moving on to our phase one trial, this is a very standard single ascending dose, multiple ascending dosing design, multiple cohorts. It's being run in Australia. We estimate about 150 subjects in this study. We're also planning to do a food effect study as well. We're not expecting a food affect, but we want to work that out in the clinic and make sure that's the case. So what we have disclosed a couple of months back is that 479 has a half-life of about three to four days. And, again, this is something that will allow us to hopefully have very, very tight control with a once-daily dosing regimen. The multiple ascending dose portion of the trial was then extended to about 14 days, and the purpose of that was to try to achieve basically steady-state levels. Good rule of thumb is that about four to five half-lives will get you to steady-stage, and we think at about 14-days we should be getting close to that. As I mentioned, in terms of what we hope to see, we're hoping to see endogenous PTH levels go down about 50% and serum calcium to go up about 0.5 mcg per deciliter to inform what would be a starting dose in hyperparathyroidism patients. As many of you know, hyperparathiroidism is a disease where the PTH replacement needs to be titrated on a patient-by-patient basis. So we want to be at that sort of starting dose and then be able to titrate a bit higher. So we are looking for levels up around 1 mc per decilitre at our high doses. And as I said, this trial should wrap up in the first quarter. So just in the last few minutes, I want to introduce you to SCP-204, which is our new oral small molecule for Graves' disease and thyroid eye disease, which we announced just for the first time a couple of weeks ago. So we're looking at a different structure here. This is the TSH receptor. You can see that it undergoes a very large conformational change from an inactive state in blue to an active state in that more magenta color. So you can see a big conformational change on the extracellular domain. Inside the receptor, you can See a bit of a change there as well. And our goal was to come up with a compound that would prevent the binding of all autoantibodies. So Graves' disease and thyroid eye disease are diseases of autoantipodies that are directed to this TSH receptor and lead to all the hallmarks of Graves disease, including hyperthyroidism as well as thyroid eye diseases. So SCP-204 basically binds in that region. So here are some of the characteristics of the development candidates of potent oral small molecule. One of the things that's actually quite important is that we have a selective compound. There are two very closely related receptors, FSH receptor and LH receptor. These are reproductive hormone receptors, and as Graves' disease is commonly found in women of reproductive years, we don't want to affect those reproductive hormone receptors. The compound has excellent pharmaceutical properties, and we project this one also to be a once-daily oral dose as well. And it has completed GLP toxicology studies, and all we saw there was signs of exaggerated on-target pharmacology, including hypothyroidism. Phase 1 is on track here to begin in Q1 of 2027. I'm going to share just a little bit of the data. that we shared, again, at the American Thyroid Association meeting just about a week and a half ago. So SCP-204 is, in this case, dosed to a rat, but it's dosed after dosing a Graves-to-Patient derived antibody, which is called M22. That's shown in the diagram there. When M22 is dosed, You see in the upper graph, thyroid T4 hormone levels starting to go up. And then about 18 hours later, we start dosing SCP-204. For the animals that do not receive SCP-104, this is in the black curve at the top. You can see the thyroid hormone levels go up and then plateau. But we see two doses, one and three milligrams per kilogram, where you can see the thyroid T4 hormone levels basically normalizing. That little thin gray band that you see there is the normal hormone levels, so both of those land us in that normal range, which is exciting. We can also go up to a higher dose of 10 mg per kilogram, and there we get more comprehensive suppression of the receptor and a decrease in thyroid hormone levels. The reason this is exciting to us is that it provides a suggestion that we may have dose optionality. We hope to work this out in the clinic where we may Have some doses that allow us to normalize thyroid function and other doses where it allows us to fully suppress it. Now, moving on to a more chronic disease model, this is in a mouse. We've taken that same Graves disease patient-derived antibody and dosed it over and over again for an eight-week period. What happens there is the animals get a phenotype consistent with Graves' disease. Thyroid hormones go up. The thyroid gets enlarged. As you'll see, there's some significant changes in the thyroid histology. And then the eyes begin to bulge as well. For the last two weeks of the study, we add on SCP-204, and you can see some reversal of that. So looking at the figures there, we see the thyroid historology and the thyroid size. The middle photo is the Graves' mouse, and you can see some significant disruption to the thyroid histology that is now normalized when we treat SEP204, which is in the third image there. Thyroid size also starts to come down. The right side shows orbital proptosis. You can see the middle figure. That is what a mouse with thyroid eye disease looks like, very proptotic eye compared to the left image. and then we're able to normalize that as well, start to reverse that. So we're excited about the prospects of this drug. So just to kind of summarize some of the key features that I've already said, projected human half-lives about 20 to 40 hours. Again, we'll work that out in the clinic. And the preclinical safety studies were, again, all we saw were effects consistent with exaggerated on-target pharmacology, namely hypothyroidism. one thing as we start to think ahead to patients is what do we expect to see in terms of biomarkers i told you a story with pth just a little while ago where we expect endogenous pth to go down for that hyperthyroidism study for this you can think about it very similarly it involves another efficient endocrine feedback loop and there we expect tsh levels to go up which is actually quite quite exciting so hopefully we'll see that in our phase one study which is again scheduled to begin around next year and with that i'll just kind of wrap up and we can take some discussion some some questions great thank you so much jeff so starting with your um 479 hypoparathyroidism program i guess that's the most topical because the phase one data is coming up relatively soon it is in healthy volunteers but it's kind of a proof-of-concept study, right, because of the way the mechanism works. So you describe the reduction in parathyroid hormone and then the increase in serum calcium. Can you talk a little bit about what you really need to show and if we can compare that to existing therapy phase one trials? Yeah, one important thing that everybody should know is that the biology, the fundamental biology of the receptor is the same in a healthy volunteer versus a patient. So both healthy individuals and patients have the same PTH receptor in the bone and the kidney. And what we've seen is that every compound that has worked in healthy volunteers has eventually worked in patients. So it is really kind of almost a proof of concept study there, even though it's not in patients yet. with regard to comparison of the existing therapies we consider your of a path to be very much the gold standard here it's a great drug however it needs you know date daily injections it has a projected it has a simulated half-life of about two and a half days and with our half-lifes about three to four days we think we're going to be in a similar range so what we're hoping to see from our phase one are doses that could be compatible with a starting dose in hyperparathyroidism patients. That would be endogenous PTH levels going down about 50% and serum calcium going up about 0.5 mgs per deciliter. Again, that's just the starting dose for a hyperparathetism patient. We'd like to be able to extend the range a little bit further than that. They showed that in their phase one. So we're using them very much as a benchmark and hoping to see at the higher end of our spectrum, calcium ranges up to about one mic per deciliter. Okay. So you just want to be in line with what they show basically. Exactly. Okay, exactly. And can you talk about your V-Path then and maybe the unmet need that's remaining in this indication? I think there's also about 70,000 patients in the U.S. So maybe talk about how those patients are currently served and the unmet need and the need for an oral therapy. Yeah. So there are about 70, to 80,000 patients within the United States. And basically, as Jeff had mentioned, these patients, their parathyroid glands have been removed, so they can't make PTH. So the ideal therapy for these patients is PTH replacement. Current standard of care is actually calcium and vitamin D. And so So YorvaPath is the first peptide replacement that's available. Again, as Jeff said, it's a daily injection. Right now it's being primarily used for the more severe patients, patients who can't get under control with calcium or vitamin D, maybe at risk for ER visits as a result of it. There's a huge unmet need. We believe that all patients should be on PTH replacement therapy. And we believe an oral small molecule really has the ability to expand the treatable patient population. Right now, the thought of going on a daily injection for the rest of your lives, again, these patients are diagnosed very early in their lives, so they'll be on treatment for decades. They really would like an oral alternative. And so certainly patients who may be a little bit more moderate in nature are certainly asking for an oral alternate, but frankly, even those who are more severe right now on the injectables are looking to have an oral option too, simply because, again, being treated for a long period of time for the resto of their lives and really helping to get under control with the PTH replacement versus calcium. Okay, so it sounds like the main patient population for an oral would be the milder patients, but then also potentially the more severe patients. Really, the oral can be used across the entire spectrum, but we think right now certainly the more moderate patients, and some of them are just less interested in going on an injectable therapy, especially because it's daily, it's a little bit burdensome for them, and so that's why we believe an oral has the option to be able to expand it to more patients right now that might currently be open for an injectable therapy. Okay. And can you talk about other, actually before then, why is it so difficult to develop an oral small molecule for this receptor? Because it seems quite straightforward. Why wouldn't you want to have an oral for this? Yeah, it's easier said than done. So several big pharma companies have actually tried to screen this receptor and find small molecules. It's just very difficult to find a small molecule that mimics a peptide. It's been kind of a historical challenge in the GPCR space and proved to be particularly difficult for this receptor. And as far as I know, we are the only company that's developed a small molecule that is effective on this receptor, good enough to hopefully show some data in a phase one trial. There's some more competition coming, I think. And one, I think, is also an oral drug. So can you talk about where those therapies might end up being positioned and how you differentiate against the other oral? So right now we're the only oral PTH product that's out there. The other oral that's in development right now is a product called Encallerate, which has actually targeted the calcium-sensing receptor. So a different mechanism of action. Its first path for development was for a special subpopulation called the ADH1 patients. And its mechanism is one, as I said, through the calcium-sensing receptor. And so for that mechanism to work, you actually need intact PTH, parathyroid tissue, to be able to produce PTH. Again, in the post-surgical patients, which is where we're focusing, a lot of patients have actually had this parathyroid glands removed, or maybe there's only a portion that's remaining. And so mechanistically, it's very different. It's done a very nice job in terms of balancing urine calcium. The phase three that's underway right now actually measures a slightly different endpoint. So the real key question here is, is it a suitable mechanism for post-surgical patients? It's not. As well, we believe, again, a full PTH replacement really kind of going at the heart of what's missing within these patients. Maybe a more direct approach, but we'll see what the phase three data looks like with this other alternative. But given, again since it's a different mechanism, we'll just have to see whether it's going to be able to stack up relative to PTH replacement or not. And in terms of pricing, I know it's way too early to talk about pricing for your drug, but in general, in these kind of rare diseases, do the oral drugs have a lower price than the injectable drugs, or how does that usually work? Again, way too earlier to talk. To talk about that, it really focuses on really what the benefit is to the patient. And so, again, as we continue to develop our drug, think about the benefits being provided for the patient, we'll be able to cross that barrier at that particular point in time. Okay. And you mentioned titration. How will that play out if this succeeds in infectious patients? Yeah, so again, we can lean on the learnings of the injectable peptides. So typically what would happen is a patient would start on a given dose, and those individuals are typically on calcium and vitamin D supplements, and so there's a titration protocol that we will need to develop in our Phase II trial where we will dose up our drug. At the same time, we dose down the calcium and vitamin D supplements. So again, fortunately, there's been some precedent for how to do that with the injectable peptides. And we will probably start with a titration protocol much like that. It's something that goes over a number of weeks to get somebody into that right range. And one of the endpoints in some of these trials is freedom from excessive calcium supplements and vitamin B as well. Okay. And then in terms of timelines for this program, should we expect similar trial designs and timelines as your VPath, given it's kind of a similar approach? Yeah, I think there's going to be some opportunities to go a little bit more quickly than they did. Just to kind of lay things out, if we finish our Phase 1 trial in Q1 of 2027, I Think we hope to be in our Phase 2 trial by the second half of 2026. One of the things that we're hoping to do before starting that Phase II trial is to complete chronic toxicology studies, and we want those chronic toxicologist studies done so that we can enroll patients from that Phase III trial into an open-label extension so that if they are benefiting from the drug, they can continue without having to go off of it. Okay, great. Phase II programs are typically on the scale of dozens of patients. The goal of the Phase 2 program is to try to get to the right starting dose. We'll probably explore a couple of those, as well as that right titration protocol. Okay. Perhaps we can move to your thyroid eye disease, Graves' disease program. Earlier in development, you said you're going to be starting the Phase 1 in the next few months. what's the thought behind this as we think about the current treatment landscape and same sort of question what's The Unmet Need and why the need for an oral therapy? Sure, so this program again is targeted to Graves' disease as well as thyroid eye disease, again thyroid eye disease is a major manifestation of Graves disease, at least 40% of patients develop some symptomatology of thyroid eye disease. And so within Graves' disease, there hasn't been a lot of novel development for quite a long period of time, but there's still quite a bit of unmet need here. Within Graves disease, patients are currently treated with antithyroid drugs. Many patients relapse. Many patients don't hit remission. And as we know, as things progress into thyroid eye disease, very few options for more mild patients and some options for the more moderate to severe. So each of these different patients within the spectrum have ongoing unmet need here. TSHR, one of the really exciting things about this is this is the receptor where the autoantibodies are actually generated, so it really is relevant for both disease states. And so as we think about our own development plans, we'll think about kind of how best to be able to address all of these different patient populations. Okay. And can you provide some more detail on what the phase one study could look like and what you hope to see and when that data could be shared? Sure. So like I said, it's a disease with a very efficient endocrine feedback loop. So we're going to start in healthy volunteers. It'll be a standard sort of single ascending dose, multiple ascending dosed design. What we hope to see there is endogenous TSH now going up. And then if we get up to high enough dose levels, see the thyroid hormones starting to come down. so that's what we'll be looking for initially one of the things we'd like to do shortly thereafter is get into some Graves disease patients and demonstrate that we can see the same thing with regard to timing if we get that trial started in the first quarter the hope would be to have that healthy volunteer data before the end of 2027 great maybe in the last few minutes we could touch on your x2 program quickly where are you at with this i know there was um you know some hope for more traditional kind of mast cell driven diseases chronic spontaneous urticaria and those unfortunately failed and you've got some other competitors which have programs, and one of them has decided to go into migraine. So curious how you're thinking about these indications and whether migraine could be a potential indication for you to explore. Yeah, so one of the really exciting things about X2 and mast cell diseases is there's a variety of different diseases where mast cell activation seems to be implicated. As you had mentioned, the original strategy was to focus on a large CSU study. Jeff can talk a little bit about our product profile and our excitement around 631 really being one of the best molecules out there. But certainly relative to that data, we want to take a step back and think about some other approaches. We've decided to take an approach which is more focused on smaller studies that are more signal-finding to really identify indications where X2 can play a critical role here. And so specifically as it relates to migraine, there's a wealth of data that's emerging, certainly as it relays to mast cells really being important relative to migrain and X2 being present, not to mention the fact that several of the neuropeptides, like PACAP, are also agonists for the X2 receptor. So there's lot of wealth of evidence coming together why migraine might be a very relevant indication here. Rather than jumping into a large Phase II study, what we're trying to identify is what can be a smaller signal-finding study, whether it be a challenge study or another design in nature, to be able to really see if there's a signal here relative to migraine, and then we would jump into a larger phase, too. So as we think about the other host of indications, things like interstitial cystitis or asthma as well, we're really trying to think about what might those study designs be to see whether we can get a signal. But, Jeff, maybe you can speak to a little bit about the profile. Yeah, I can share a little Bit about the Profile. We think we've got a very, very good molecule here. We've got an unique mechanism called a negative allosteric modulator, which is a situation where we bind outside of this very promiscuous binding pocket on the receptor. The receptor, just for those of you who haven't thought about it much, has literally dozens of endogenous ligands that bind to it. And our profile was to come up with a compound that would prevent the activation of the receptor by all agonists of this. And we came up with the very unique mechanism, which is that the compound, when it binds into the transmembrane to maintain the receptor, results in a conformational change that closes the binding packet off completely so that none of the endogenous agonists can bind it. And our compound has a very, very slow off rate. It's on there for hours when the compound's on There. So we think it's also important to have nearly complete inhibition of the receptor. So going all the way up to probably 99% receptor occupancy we think is going to be important because mast cells are kind of primed to degranulate if a little bit of activation sneaks through. So the goal is to have a great compound. We've got that great compound, very safe in the phase one trial, once daily pill, and we think it's got an opportunity to cross a whole bunch of medications. Great. I think that's all we have time for, but thank you, Jeff. Thank you, Liz. Thank you everyone for joining.

Company
SEPTERNA INC
Keywords
SEPTERNA INC